Synonyms: compound A-290 [WO2018013597A1] | RMC-4630 | RMC4630 | SAR-442720 | SAR442720 | SHP2-IN-7
Compound class:
Synthetic organic
Comment: RMC-4630 (Revolution Medicines) is a clinical stage oral, allosteric SHP2 (PTPN11) inhibitor [1] that is being evaluated for efficacy against advanced solid tumours. SHP2 is a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signalling pathway which is often hyperactivated in tumours.
We matched RMC-4630's chemical structure to the INN 'vociprotafib' which was released in the WHO's proposed INN list 127 on 21 July 2022. |
|
References |
1. Jogalekar A, Won W, Koltun ES, Gill A, Mellem K, Aay N, Buckl A, Semko C, Kiss G. (2018)
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors. Patent number: WO2018013597A1. Assignee: Revolution Medicines, Inc.. Priority date: 12/07/2016. Publication date: 18/01/2018. |